Literature DB >> 19921971

Neurotrophic factors in serum following ECT: a pilot study.

Ole Grønli1, Geir Øyvind Stensland, Rolf Wynn, Reidun Olstad.   

Abstract

We examined changes in serum levels of a selection of neurotrophic factors, TSH, HGH and cortisol in conjunction with ECT treatment. Fifteen patients suffering from affective disorders were included, all were treated with antidepressants and psychotherapy and 10 also with ECT. The patients were examined clinically and with blood samples during treatment. Serum levels of cortisol, thyroid stimulating hormone (TSH), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neuropetide Y (NPY) and human growth hormone (HGH) were studied. No significant changes were found in levels of NGF, BDNF, NT3, HGH and TSH. A change in NPY levels was statistically significant, but of uncertain clinical value as it affected only two patients. Levels of cortisol rose significantly during treatment. We did find significant correlations between the base values of NGF and HAM-D scores at inclusion and between the end-values of NT3 and NPY and the HAM-D scores prior to discharge. We were unable to reproduce findings from animal studies suggesting that a range of neurotrophic factors rise during ECT treatment. This may be because of physiological differences between animals and humans or, possibly, a result of the small number of patients included in this pilot study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19921971     DOI: 10.3109/15622970701586323

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  12 in total

1.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

Review 2.  The treatment of hallucinations in schizophrenia spectrum disorders.

Authors:  Iris E C Sommer; Christina W Slotema; Zafiris J Daskalakis; Eske M Derks; Jan Dirk Blom; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2012-02-24       Impact factor: 9.306

3.  Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients.

Authors:  Jan Malte Bumb; Suna Su Aksay; Christoph Janke; Laura Kranaster; Olga Geisel; Peter Gass; Rainer Hellweg; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-18       Impact factor: 5.270

Review 4.  Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484).

Authors:  M L Molendijk; P Spinhoven; M Polak; B A A Bus; B W J H Penninx; B M Elzinga
Journal:  Mol Psychiatry       Date:  2013-08-20       Impact factor: 15.992

5.  Association study of early-immediate genes in childhood-onset mood disorders and suicide attempt.

Authors:  John Strauss; Stuart McGregor; Natalie Freeman; Arun Tiwari; Charles J George; Maria Kovacs; James L Kennedy
Journal:  Psychiatry Res       Date:  2012-03-27       Impact factor: 3.222

6.  Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis.

Authors:  André R Brunoni; Rodrigo Machado-Vieira; Carlos A Zarate; Erica L M Vieira; Leandro Valiengo; Isabela M Benseñor; Paulo A Lotufo; Wagner F Gattaz; Antonio L Teixeira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-08-27       Impact factor: 5.067

7.  Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression.

Authors:  Laura Gedge; Ashley Beaudoin; Lauren Lazowski; Regina du Toit; Ruzica Jokic; Roumen Milev
Journal:  Front Psychiatry       Date:  2012-02-24       Impact factor: 4.157

8.  Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review.

Authors:  Yen-Wen Chen; Pao-Yen Lin; Kun-Yu Tu; Yu-Shian Cheng; Ching-Kuan Wu; Ping-Tao Tseng
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-01       Impact factor: 2.570

Review 9.  Brain-Derived Neurotrophic Factor and Antidepressive Effect of Electroconvulsive Therapy: Systematic Review and Meta-Analyses of the Preclinical and Clinical Literature.

Authors:  M Polyakova; M L Schroeter; B M Elzinga; S Holiga; P Schoenknecht; E R de Kloet; M L Molendijk
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

Review 10.  Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all?

Authors:  E M van Buel; K Patas; M Peters; F J Bosker; U L M Eisel; H C Klein
Journal:  Transl Psychiatry       Date:  2015-07-28       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.